RETRACTED: A Randomized, Participant‐ and Evaluator‐Blinded, Matched‐Pair, Prospective Study Comparing the Safety and Efficacy Between Polycaprolactone and Polynucleotide Fillers in the Correction of Crow's Feet
Journal of Cosmetic Dermatology · 2025-01 · 24 (1)
DOI: 10.1111/jocd.16576 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 23.09.2024. Verfasst von Sun Young Choi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong-si, Gyeonggi-do, Republic…. Hauptthemen laut MEDLINE: Polyesters, Skin Aging, Dermal Fillers, Cosmetic Techniques. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was funded by DexLevo, Inc..
Abstract (Originalsprache)
Background
Dermal fillers have gained widespread popularity for facial cosmetic enhancement and anti‐aging treatments. Recently, polycaprolactone (PCL) and polynucleotides (PN) fillers have emerged as promising options owing to their safety and long‐lasting effects.
Objectives
This study aimed to compare the efficacy and safety of a novel PCL‐based dermal filler (DLMR01) with purified PN filler (RJR: Rejuran) in correcting crow's feet wrinkles. Materials and Methods A randomized, evaluator‐blinded, prospective split‐face study was conducted with 218 healthy Asian participants. The primary outcome was in the improvement rate of the Crow's Feet Grading Scale (CFGS) at rest after 12 weeks. Secondary outcomes included the improvement rate of the CFGS at expression and rest at earlier time points, changes in CFGS, and the Global Aesthetic Improvement Scale (GAIS) assessment.
Results
The results showed that DLMR01 was not inferior to RJR in improving crow's feet wrinkles, with a significantly higher CGFS improvement rate at week 12. Both fillers demonstrated good safety profiles, with mild and tolerable adverse events. No serious adverse events were reported during the study period.
Conclusion
DLMR01, a PCL‐based dermal filler, showed effectiveness and safety in improving wrinkles described as crow's feet. The study suggests that DLMR01 could be a promising option for noninvasive anti‐aging treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong-si, Gyeonggi-do, Republic of Korea.
- Department of Dermatology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
ORCID-Profile: Sun Young Choi, Young Gue Koh, Kwang Ho Yoo, Hye Sung Han, Joon Seok, Beom Joon Kim
Förderung
- This work was funded by DexLevo, Inc.
Zitieren
APA
Choi, S. Y., Koh, Y. G., Yoo, K. H., Han, H. S., Seok, J., & Kim, B. J. (2025). RETRACTED: A Randomized, Participant‐ and Evaluator‐Blinded, Matched‐Pair, Prospective Study Comparing the Safety and Efficacy Between Polycaprolactone and Polynucleotide Fillers in the Correction of Crow's Feet. Journal of Cosmetic Dermatology, 24(1). https://doi.org/10.1111/jocd.16576
Vancouver
Choi SY, Koh YG, Yoo KH, Han HS, Seok J, Kim BJ. RETRACTED: A Randomized, Participant‐ and Evaluator‐Blinded, Matched‐Pair, Prospective Study Comparing the Safety and Efficacy Between Polycaprolactone and Polynucleotide Fillers in the Correction of Crow's Feet. Journal of Cosmetic Dermatology. 2025;24(1). doi:10.1111/jocd.16576
BibTeX
@article{Choi2025,
author = {Choi, Sun Young and Koh, Young Gue and Yoo, Kwang Ho and Han, Hye Sung and Seok, Joon and Kim, Beom Joon},
title = {RETRACTED: A Randomized, Participant‐ and Evaluator‐Blinded, Matched‐Pair, Prospective Study Comparing the Safety and Efficacy Between Polycaprolactone and Polynucleotide Fillers in the Correction of Crow's Feet},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
volume = {24},
number = {1},
doi = {10.1111/jocd.16576}
}
EUVIMED